ストックスクリーナーアプリを入手
1.41
3.68%
0.05
前日終値:
$1.36
開ける：
$1.36
24時間の取引高:
11,484
Relative Volume:
0.22
時価総額：
$2.96M
収益：
-
当期純損益:
$-9.32M
株価収益率:
-0.1109
EPS:
-12.7107
ネットキャッシュフロー:
$-7.30M
1週間 パフォーマンス:
-2.08%
1か月 パフォーマンス:
-2.76%
6か月 パフォーマンス:
-42.45%
1年 パフォーマンス:
-78.15%
1日の値動き範囲:
$1.3307
$1.505
1週間の範囲:
$1.32
$1.6885
52週間の値動き範囲:
$1.32
$7.461
Tharimmune Inc Stock (THAR) Company Profile
THAR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.41 | 2.96M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc (THAR) 最新ニュース
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Weatherford Democrat
Game-Changing Oral Alternative to Injectable Antibody Achieves Key Milestone - StockTitan
Tharimmune leverages Epiclick platform to expand pipeline - BioWorld Online
Hillstream Biopharma stock hits 52-week low at $1.36 - Investing.com
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Markets Insider
Tharimmune unveils novel cancer treatment HS1940 - Investing.com India
Tharimmune unveils novel cancer treatment HS1940 By Investing.com - Investing.com South Africa
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 58.6% - Defense World
Tharimmune appoints new CFO following resignation By Investing.com - Investing.com Canada
Tharimmune Says Thomas Hess Resigns As CFO -February 27, 2025 at 05:34 pm EST - Marketscreener.com
Tharimmune Says Thomas Hess Resigns As CFO - TradingView
Tharimmune appoints new CFO following resignation - Investing.com
Hillstream Biopharma stock hits 52-week low at $1.83 By Investing.com - Investing.com Canada
Hillstream Biopharma stock hits 52-week low at $1.83 - Investing.com
Financial Analysis: ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) - Defense World
Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter
Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World
Larchmont broker accused of years-long insider trading scheme - Westfair Online
Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy? - Defense World
Tharimmune to Present at the Microcap Conference 2025 - Bellingham Herald
Tharimmune to Present at Microcap Conference 2025, Showcase Growth Strategy - StockTitan
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - ACCESS Newswire
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis - ACCESS Newswire
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - ACCESS Newswire
tharimmune CEO Randy Milby buys shares worth $9,752 - Investing.com India
tharimmune CEO Randy Milby buys shares worth $9,752 By Investing.com - Investing.com Canada
Tharimmune files to sell 1.44 million shares of common stock by selling shareholders - MSN
Tharimmune, Inc. Appoints Sanam Parikh to Its Board of Directors - Marketscreener.com
Tharimmune plans Phase 2 trial for itch treatment TH104 - Investing.com
Tharimmune plans Phase 2 trial for itch treatment TH104 By Investing.com - Investing.com UK
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Eagle-Tribune
Tharimmune Advances TH104 Clinical Program: Phase 2 Trial Set for 2025 After Positive Phase 1 Results - StockTitan
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.55% - MSN
Tharimmune announces $2.02M private placement; shares up - MSN
Tharimmune (NASDAQ:THAR) Coverage Initiated at Rodman & Renshaw - Defense World
Rodman & Renshaw Initiates Coverage of Tharimmune (THAR) with Buy Recommendation - MSN
Tharimmune secures $2.02 million in private funding By Investing.com - Investing.com Nigeria
THARTharimmune, Inc. Latest Stock News & Market Updates - StockTitan
Tharimmune secures $2.02 million in private funding - Investing.com
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs - Eagle-Tribune
Tharimmune Secures $2M Strategic Investment to Advance Chronic Pruritus Treatment Pipeline - StockTitan
Rodman & Renshaw sets price target on Tharimmune shares, rating Buy - Investing.com
Tumor necrosis factor (TNF)-alpha Inhibitor Market Will Witness Growth with Emerging Therapies by 2034 | - EIN News
Tharimmune Inc (THAR) 財務データ
収益
当期純利益
現金流量
EPS
Tharimmune Inc (THAR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Appajosyula Sireesh | Chief Operating Officer |
Nov 13 '24 |
Buy |
2.02 |
5,000 |
10,096 |
10,758 |
| MILBY RANDY | CEO |
Oct 08 '24 |
Buy |
2.09 |
2,500 |
5,221 |
12,934 |
| Appajosyula Sireesh | Chief Operating Officer |
Oct 08 '24 |
Buy |
1.93 |
5,000 |
9,650 |
16,364 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):